Active Surveillance for Localized Prostate Cancer

Cancer Overdiagnosis and Overtreatment.- Can We Screen and Still Reduce Overdiagnosis?.- The Role of Fear in Overdiagnosis and Overtreatment.- Ethical and Legal Considerations in Active Surveillance for Prostate Cancer.- Gleason 6 Tumors Should Still Be Labeled As Cancer.- Risk Based Selection for Active Surveillance.- Surveillance at the Margins: Management of High Volume Gleason 6, PSA > 10, or Gleason 3+4.- How Should Patients on Active Surveillance be Followed?.- Triggers for Intervention.- MR Imaging in Prostate Tumor Volume Assessment: How Accurate?.- Can MRI Replace Biopsy in Men on Surveillance?.- Tissue Based Markers for Risk Prediction.- International AS Registry: The Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance Initiative.- Better Informed Decision Making to Optimize Patient Selection.- How Does QOL Compare Between Surveillance and Active Treatment?.- The Potential Benefits of Diet and Physical Activity among Active Surveillance Patients with Low-Burden Prostate Cancer.- Is there a Role for Pharmacologic Manipulation to Prevent Progression in Men on Active Surveillance? The Role of 5-ARIs, Statins, and Metformin.- The Update of Active Surveillance around the World: Utilization and Outcomes.- Tissue Preservation - Active Surveillance and Focal Therapy as Complimentary Strategies.- The Economics of Active Surveillance for Prostate Cancer.- Research Questions in Active Surveillance.